1 August, 2024
The Australian Government’s Medical Research Future Fund (MRFF) has awarded $4 million to the Australian National University (ANU) for a “National Platform for Therapeutic mRNA Development”. This project will be led by Professor Thomas Preiss, Professor and Director of Shine Dalgarno Centre for RNA Innovation (pictured on the right).
The project aims to establish a national platform for the development of therapeutic mRNA, with one of three initial pilot projects focusing on macular degeneration. It seeks to advance the understanding and application of mRNA-based therapies to improve the lives of individuals affected by macular degeneration. The anticipated outcomes include the development of novel mRNA-based treatments whilst enhancing collaboration between researchers, industry and consumer groups to improve treatment accessibility.
Retina Australia is proud to announce that it is a Project Partner on this collaborative project.
List of Partner Organisations:
Commonwealth Scientific and Industrial Research Organisation, Canberra Health Services, Retina Australia, Telethon Kids Institute, Vivazome Therapeutics Pty Ltd, Amaroq Therapeutics Pty Ltd, A.T.A Scientific Pty Limited, Cytoseek Limited, Therapeutic Innovation Australia Limited, Monash University, Yaman Biotech Pty Ltd, The University of Queensland, Healthcare Consumers Association of the A.C.T. Incorporated, M Reiwoldt Holdings Limited, MTP-IIGC Ltd, University of New South Wales, MDimune Inc., Australian National University, Australian Red Cross Society, The University of Technology Sydney, Lung Foundation Australia, Myeloid Therapeutics Pty Ltd, University of South Australia
https://retinaaustralia.com.au/mrff-grant-awarded-for-national-platform-for-therapeutic-mrna-development/
Other News
Meet Retina Australia’s 2027 research grant recipients
Two new research projects will tackle different challenges in developing potential treatments for inherited...
October CEO update: recognition, connection and progress
October has been a month of recognition, connection and continued progress towards a future...
Encouraging early progress in Australian retinal implant trial for inherited retinal disease
Early observations from a participant with Stargardt disease offer...